Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus
- Authors
- Hyun, M. H.; Lee, Y. -S.; Kim, J. H.; Je, J. H.; Yoo, Y. J.; Yeon, J. E.; Byun, K. S.
- Issue Date
- Jun-2017
- Publisher
- Blackwell Publishing Inc.
- Citation
- Alimentary Pharmacology and Therapeutics, v.45, no.12, pp 1493 - 1505
- Pages
- 13
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Alimentary Pharmacology and Therapeutics
- Volume
- 45
- Number
- 12
- Start Page
- 1493
- End Page
- 1505
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/4974
- DOI
- 10.1111/apt.14068
- ISSN
- 0269-2813
1365-2036
- Abstract
- Background
Preventing mother to child transmission of chronic hepatitis B infection in the setting of a high maternal viral load is challenging. The idea has emerged from antepartum tenofovir treatment with combination immunoprophylaxis.
Aims
To demonstrate the efficacy and safety of tenofovir to prevent mother to child transmission of hepatitis B virus.
Methods
PubMed, EMBASE, and Cochrane databases were searched through August 16, 2016. Comparative trials of second or third trimester tenofovir administration vs. controls for patients with chronic hepatitis B infection and non-comparative case series assessing mother to child transmission rates and evaluating maternal and foetal safety outcomes were included.
Results
Ten studies (one randomised controlled trial, four non-randomised controlled trials and five case series) that enrolled 733 women were included. The pooled results from comparative trials (599 pregnancies) showed that tenofovir significantly reduced the risk of infant hepatitis B surface antigen seropositivity by 77% (odds ratio=0.23, 95% confidence intervals=0.10-0.52, P=.0004) without heterogeneity (I2=0%). In the case series analysis (134 pregnancies), only two cases (1.5%) of mother to child transmission with extremely high maternal viral load and non-compliance to treatment were identified. Maternal and foetal safety parameters including congenital malformation and foetal death were re-assuring.
Conclusions
For pregnant women with high hepatitis B virus DNA levels, tenofovir administration in the second or third trimester can prevent mother to child transmission when combined with hepatitis B immunoglobulin and the hepatitis B vaccine. Tenofovir is safe and tolerable for both the mother and foetus.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
- 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.